Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Vali A. Papadimitrakopoulou, MD, and Gideon Michael Blumenthal, MD, on NSCLC: An Updated Pooled Analysis

Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Gideon Michael Blumenthal, MD, of the US Food and Drug Administration, discuss milestone analyses with immune checkpoint inhibitors, targeted therapy, and standard therapy in metastatic non–small cell lung cancer trials submitted to the FDA (Abstract 9010).

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the SQUIRE Trial

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.

To see Dr. Paz-Ares discuss this video in Spanish, please click here.

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results from the SQUIRE Trial (Spanish Language Version)

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line treatment of patients with stage IV squamous non–small cell lung cancer.

To see the English language version of this video, please click here.

Hepatobiliary Cancer

Ghassan K. Abou-Alfa, MD, on Sorafenib and Doxorubicin for Advanced Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses findings of this phase III study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (Abstract 4003).

CNS Cancers

Martin J. Van Den Bent, MD, PhD, on Anaplastic Glioma: Results from the CATNON Trial

Martin J. Van Den Bent, MD, PhD, of the Daniel den Hoed Cancer Center, discusses the interim analysis of the EORTC phase III study on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion (Abstract LBA2000).

Jun

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Vali A. Papadimitrakopoulou, MD, and Gideon Michael Blumenthal, MD, on NSCLC: An Updated Pooled Analysis

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the SQUIRE Trial

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results from the SQUIRE Trial (Spanish Language Version)

Ghassan K. Abou-Alfa, MD, on Sorafenib and Doxorubicin for Advanced Hepatocellular Carcinoma

Martin J. Van Den Bent, MD, PhD, on Anaplastic Glioma: Results from the CATNON Trial

Switching to Camizestrant After Detection of an ESR1 Mutation Improves Progression-Free Survival for Some Patients With Advanced Breast Cancer

Adding Atezolizumab to Adjuvant Chemotherapy Improves Disease-Free Survival in dMMR Colon Cancer

Structured Exercise Program Improves Survival in Some Patients With Colon Cancer

Impact of Dietary Patterns on Survival in Stage III Colon Cancer

Perioperative Durvalumab Boosts FLOT Chemotherapy Benefit for Some Gastric Cancers